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The Contribution of Leucocytes to the Antimicrobial Activity of Platelet Rich 
Plasma Preparations: a systematic review 
INTRODUCTION 
The topical use of autologous Platelet Rich Plasma (PRP) as a biological accelerator of 
the healing process has been safely used as a form of treatment for wounds since the 
1990s [1,2]. Platelets promote wound healing through their release of a vast array of 
granular components   and biological mediators, including growth factors (which promote 
the chemotaxis of leucocytes, fibroblasts and myofibroblasts, as well the synthesis of 
extracellular matrix (ECM) and promotion of angiogenesis [2-4]). Additionally, platelets 
are well recognized for their role in the host defense system [5], which results from the 
release of antimicrobial peptides (AMP) contained in the granules, and through inducing 
expression of antimicrobial proteins from other cells [5-7].  
Many different procedures have been used to obtain PRP from whole blood, leading to 
heterogeneity in preparations [8]. During this process it is also possible to include 
leucocytes in the final preparation (which would then be referred to as Leucocyte-platelet 
rich plasma (L-PRP) [9]) at different concentrations, or totally exclude leucocytes from 
the preparation.  
Although a large body of literature exists detailing the wound healing and antibacterial 
properties of platelets, the inclusion of leucocytes in the PRP preparation has been 
neglected for many years [9]. The potential role(s) of leucocytes included in PRP has yet 
to be fully explored despite the well-recognized role for leucocytes in tissue repair and 
host defense [9-11], and there are contrasting reports regarding the benefits of including 
leucocytes within PRP preparations [12]. Several small but promising studies have 
demonstrated benefits in wound care of L-PRP, and antimicrobial properties have been 
reported [7,13,14]. However other authors discourage their inclusion in PRP, reporting 
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that this stimulates a pro-inflammatory environment that may negatively influence tissue 
regeneration [15]. Furthermore, an in vitro study recently suggested that the inclusion of 
leucocytes in PRP preparations does not enhance the bactericidal activity of PRP [16] .  
The potential natural antimicrobial properties of a PRP preparation is an alluring addition 
to a preparation already recognized to the beneficial for wound healing. It is however 
unclear which components of the preparation are important for the bactericidal effect.  
Laboratory studies exploring the antimicrobial effect(s) of L-PRP are still ongoing; 
therefore it is timely to evaluate the current literature on this subject. It is beyond the 
remit of the work to detail how leucocytes exert their antimicrobial effects, but the reader 
is directed to the elegant review published in 2012 by Bielecki et al.[9]. 
 
In this review we aim to summarise and evaluate the literature on the contribution of 
leucocytes included in L-PRP to the antimicrobial properties of the preparation as a 
whole. Acknowledging the wide and poorly defined method variations in preparation of 
L-PRP, and the reported challenges in comparing the clinical and antimicrobial effects of 
PRP preparations [9, 18], the studies included in this review have been analysed in terms 
of the methodology used i) for the preparation of L-PRP and the other blood-derived 
products , ii) to study the antimicrobial activity. This should help to inform clinical 
practice and additional research in this promising field. 
 
METHODS  
Data Sources 
A literature review of publications was performed by two independent reviewers in May 
2016 in the Ovid MEDLINE, PubMed (1946-2016) and EMBASE (1974-2016) database. 
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 In addition, the reference lists of all identified articles were examined to identify relevant 
papers that were not captured by electronic searches. MeSH Terms, Headings with 
Boolean operator for PubMed search were:  ["platelet-rich plasma"[MeSH Terms] OR 
"platelet-rich"[All Fields] AND "plasma"[All Fields]] OR "platelet-rich plasma"[All 
Fields] OR ["platelet"[All Fields] AND "rich"[All Fields] AND "plasma"[All Fields] ] 
OR "platelet rich plasma"[All Fields] ] AND ["anti-infective agents"[Pharmacological 
Action] OR "anti-infective agents"[MeSH Terms] OR ["anti-infective"[All Fields] AND 
"agents"[All Fields] ] OR "anti-infective agents"[All Fields] OR "antimicrobial"[All 
Fields] ].  
In addition, the terms “exp Platelet-Rich Plasma/  OR “exp Platelet-Derived-Growth 
Factor/” OR the following keywords: “L-PRF” OR “L-PRP” OR “Platelet Rich Fibrin” 
OR [“PLG” AND “Platelet-Rich Plasma"] OR [“PRF” AND “Platelet-Rich Plasma"] and 
“exp antimicrobial/”  were used in MEDLINE and  EMBASE. 
Study selection criteria 
Study eligibility was defined using the population, intervention, comparator, outcome, 
and study design approach (PICOS) [17]. The inclusion and exclusion criteria are 
summarized in Table 1. Study selection was performed through two levels of screening. 
In the first level, abstracts were reviewed for the inclusion and exclusion criteria. In the 
second level screening, all articles filtered through the first level were fully read and the 
selected inclusion and exclusion criteria applied. The eligibility of the studies was 
assessed independently by two authors, and discrepancies were resolved by discussion. 
The ultimate list of included articles was designated with the agreement of all the authors. 
To be included, studies needed to clearly address the leucocyte inclusion in the 
composition of PRP and report the haematology values. Comments, case reports and 
review papers were excluded. Studies with duplicate publications were only included 
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once, using the most recent publication. Only in vitro and human studies were included.  
Animal studies were excluded, since i) none of the animal studies extracted from the 
literature search compared PRP preparations including leucocytes to those without, and 
ii) the environment in an animal model is different to a human model and does not 
translate to the full potential of PRP-like products in terms of bactericidal capabilities for 
wound treatment. 
 
Data extraction and analysis  
Data were recorded using a data extraction table (Table 2). The following data from the 
full text of included papers were extracted and analysed: study design, methodology used 
for L-PRP preparation, haematological values of leucocytes and platelets, preparation 
comparators (different preparations tested), platelets activators, bacterial strains tested, 
other parameters tested, microbiological assay, overall antimicrobial effect. A formal 
statistical analysis was not performed because of the methodological heterogeneity, and 
small numbers of eligible studies.  
 
RESULTS 
Articles included 
The literature search yielded 686 articles.  From a first screening of the titles and 
abstracts, 643 citations were removed since they were not relevant to the topic or were 
duplicates. Therefore 43 articles progressed to the second level of screening. After 
retrieval of full text, review of each article, and application of inclusion and exclusion 
criteria (and addition of one article discovered by review of references), 11 papers were 
included in the final analysis [14,16,18-26] (Figure 1 and Table 2).  
 5 
Study design 
All the 11 papers included in the review were in vitro studies where various amounts of 
blood were drawn according to the requirements of the individual L-PRP preparation 
method (varying from 53 ml to 300 ml of blood from each donor). Blood was drawn from 
healthy human volunteers in eight studies [14,16,18-21,23,24,27], from patients with 
diabetic ulcers in one study [22], from horses in one study [25], and from rabbits in one 
study [26]. Only the in vitro data has been analysed for this latter study [26]. 
Parameters tested 
The antimicrobial activity of L-PRP was tested against different bacterial strains 
including Staphylococcus aureus both methicillin-sensitive (MSSA), and resistant 
(MRSA), Escherichia coli, Enterococcus faecalis, Enterobacter cloacae, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Staphylococcus epidermidis, Bacillus cereus, 
Bacillus subtilis, Streptococcus pyogenes, Neisseria gonorrhoeae, and Propionibacterium 
acnes. In addition to the antimicrobial properties of the biomaterial, other leucocyte and 
platelet parameters were also included in some studies. Moojen et al. [19] for example 
aimed to evaluate the contribution of leucocytes with their oxidative killing action, and 
therefore included in their study measurements of myeloperoxidase (MPO) activity and 
MPO release. MPO was gradually released by thrombin-activated, and non-activated PRP 
preparations in the first hours, withno significant differences detected in the MPO 
activity, and nocorrelation between MPO concentration, activity and bacterial killing. To 
test the antimicrobial contribution of leucocytes in the preparation, Chen et al., [22] used 
apocynin, an inhibitor of NADPH oxidase activity, to block the oxidative burst action of 
leucocytes. The authors did not find difference in the antimicrobial activity of the 
preparation where leucocytes function was inhibited compared to an activated L-PRP 
preparation.  Release of different growth factors (F-4, TGF-β1, and  PDGF-BB) at 
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various incubation times were also measured in one  study [25], in order to test the 
possible antimicrobial contribution of different concentration of growth factors within 
PRP preparations, and the ability of bacteria to denature or reduce growth factors levels. 
Measurement of complement and antibody levels were also included in the study 
conducted by Wu et al. [23]. Using immunoassay kits, Mariani et al. [16] measured 
proteins released by PRP preparations, such as ‘Macrophage Inflammatory Protein’ 
(MIP)-1α (CCL3), ‘Regulated on Activation Normal T Expressed and Secreted 
protein’(RANTES), GRO-α, Interleukin (IL)-8, Interleukin (IL)-6, neutrophil-activating 
protein (NAP)-2, and stromal cell-derived factor (SDF)-1α. When the concentration of 
the proteins and the bacteria growth inhibition was tested, the proteins showed strong 
antimicrobial potential. Other parameters tested were the contribution to the antimicrobial 
effect of activated (with different activators) and non-activated PRP [21-23,25]. In Li et 
al. [26] various concentrations of bovine thrombin were used to activate L-PRP and used 
to assess the role of thrombin in the antimicrobial properties of PRP.  
Method of preparation of L-PRP and its influence of the haematological values of 
leucocytes and platelets 
The methods of L-PRP preparation used in the selected studies were considerably 
different, as shown in Table 2: single or double centrifugation, different platforms, 
different spin and centrifugation values (‘g’ standing for multiples of earth gravitational 
field and ‘rpm’ standing for revolutions per minute) and different centrifugation duration 
times. Not surprisingly the variation within the methods of preparation caused variations 
in the quantities of the haematological components of the blood products. In all the 
included studies the processing methods resulted in enrichment of platelet concentration 
of the PRP, ranging from as lowest as two-fold [20,25,28] up to ten and eleven-fold [23, 
26].  There was also a wide variation in the concentration of leucocytes in the L-PRP 
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after processing, varying from a low concentration of leucocytes used in an in vitro study 
(3.9-fold decrease from whole blood) [23]  to a high concentration (4-fold enrichment) 
[26]. None of the studies specified the differential white blood counts, so the relative 
percentage of each type of white blood cell in the L-PRP preparations is unknown. The 
viability and function of leucocytes after the PRP processing was assessed in the study 
conducted by Moojen et al. [19]. Here the authors measured MPO concentrations after a 
single step centrifugation method used to prepare L-PRP, and found that neutrophils and 
monocytes were not only viable but biologically active as shown by the rapid increase in 
MPO concentration detected shortly after the addition of L-PRP to the bacterial culture.  
Activation of L-PRP 
Of the 11 studies, 9 prepared L-PRP as a gel form by activating platelets to release their 
granular components. L-PRP was activated by different materials including calcium 
chloride, bovine thrombin, calcium gluconate, or a combination of calcium chloride with 
bovine thrombin (Table 2). Only one study evaluated the antimicrobial effect of L-PRP in 
its pure, inactivated form [24].  
 Microbiology assay 
The 11 studies included are very similar in terms of the methodologies used to test the 
biomaterials. Nine of the 11 (Table 2) used a bacterial killing assay, whereby bacterial 
cultures and the biomaterials were mixed together, incubated under agitation, and 
aliquots removed at certain time points (up to 24 hours) for serial dilution, plating and 
subsequent assessment of bacterial counts (in terms of CFU/ml). The evaluation of the 
zone of inhibition (Kirby-Bauer disk-diffusion method) was used in 3 studies [18,21,23]. 
As well as the methodologies being similar, there was good concordance in terms of the 
bacterial isolates tested, with 9 of the 11 papers testing S. aureus.  
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Antimicrobial outcomes  
To our knowledge, the first paper addressing the antimicrobial activity of a PRP 
preparation with a clear recognition of the inclusion of leucocytes, was the study 
published in 2007 by Bielecki et al. [18]. The authors conducted an in vitro study 
drawing blood from healthy human volunteers to evaluate the antimicrobial activity of 
PRP activated with bovine thrombin in a 10% calcium chloride solution (PRG, Platelet 
Rich Gel) against the most frequent bacteria responsible of wound and bone infections: 
MSSA, MRSA, E. coli (Extended Spectrum Beta Lactamase, ESBL) and non-ESBL, K. 
pneumoniae (ESBL), E. faecalis and P. aeruginosa. High concentrations of both platelets 
and leucocytes were obtained (increased by 760% and 790% respectively) using a single 
centrifugation method. The antimicrobial activity of the L-PRP preparation was 
determined using a Kirby-Bauer disc-diffusion method, and showed different effects for 
different strains, with strong antimicrobial activity detected against MSSA, MRSA and  
E. coli, whilst no bactericidal activity was found against E. faecalis, K. pneumoniae and 
P. aeruginosa. Alarmingly the addition of L-PRP to P. aeruginosa led to an actual 
increase in growth. Even though the objective of the study was not specifically to 
evaluate the antibacterial activity of different concentrations of platelets or leucocytes, 
the authors stated that within the 20 blood samples studied, no correlation between 
antibacterial activity and the value of platelets and leucocytes in the blood and the 
platelet-rich plasma was detected.  The study conducted by Moojen et al. [19] was the 
first attempt in recognising the specific contribution of leucocytes in L-PRP preparations. 
The authors used a semi-automated table top centrifuge to obtain PRP, reaching high 
concentrations of both platelets and leucocytes (platelets and leucocytes more than 7-fold 
and 3-fold enrichment, respectively). L-PRP was activated with either autologous or 
bovine thrombin, resulting in a preparation referred by the authors as PLG-AT or PLG-
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BT (Platelet-leucocyte gel autologous (AT) or bovine thrombin (BT). Other comparators 
were PPP (Platelet Poor Plasma), PRP (Platelet Rich Plasma) and PBS (phosphate 
buffered saline), the latter which acted as a control. The different preparations were used 
to test antimicrobial activity against MSSA using a bacterial killing assay. Even though 
all the four blood preparations showed antimicrobial activity,  the PRP containing high 
concentrations of both platelets and leucocytes, and activated with autologous thrombin 
(PLG-AT),  proved to be the most antimicrobial (and to give the longest duration of 
effect) compared to PRP, PPP and PRP-BT. In this study non-activated PRP and PPP 
also exhibited some antimicrobial activity, but with a more delayed effect. Autologous 
activated PRP showed the largest effect for the entire 24 hours. There were no 
preparations resulting in 100% efficiency of bacterial killing. In order to explore the 
contribution of leucocytes to the antimicrobial properties shown by the L-PRP 
preparation, myeloperoxidase (MPO) activity and MPO release at different time points of 
incubation were measured. MPO was gradually released in PLG-AT, PLG-BT and PRP 
preparations in the first few hours. The authors speculated that the stronger antimicrobial 
effect found with the PLG-AT preparation is likely due to the effect of thrombin acting 
on the antimicrobial peptides released by platelets rather than effect of leucocyte 
activation. Different preparations including low and high concentrations of platelets (and 
inclusion or exclusion of leucocytes), were used by Anitua et al. [20] to evaluate the 
bactericidal effect of the different blood products against four bacterial strains. Here a 
bacterial kill assay was performed to test the antimicrobial activity of PRP products 
against MSSA, MRSA, methicillin-sensitive S. epidermidis (MSSE) and resistant S. 
epidermidis (MRSE). The different fractions obtained from plasma after a single 
centrifugation step were: F1 (plasma), which contained a 1-fold enrichment of platelets  
and no leucocytes compared to whole blood, F3 (PRP) containing 2.5-fold  enriched 
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platelets and no leucocytes, and F3+leucocytes:1.8-fold  enrichment of platelets  and 3.9-
fold enrichment of leucocytes.  The authors found that after four hours all the fractions 
revealed bacteriostatic properties against MSSA and MRSA and MRSE. The preparation 
including leucocytes was revealed to be superior against MSSE, where it was the only 
fraction able to reduce the growth in the experiment.  In order to explore the nature of the 
antimicrobial activity of PRP and specifically to investigate which components exert this 
effect, Burnouf et al. [21] tested the effect of different blood preparations against eight 
strains of wound bacteria (four Gram positive and four Gram negative bacteria). The 
authors compared PRP (containing leucocytes), calcium chloride activated PRP (PG: 
Platelet Gel), PPP (platelet poor plasma), solvent/detergent-treated PLT lysate (S/D P-L) 
and complement inactivated preparations . All the preparations were immediately frozen 
and kept frozen at ≤-20°C until use. PRP was processed by apheresis for the blood 
samples from the two donors obtaining a 6-fold enrichment for platelets and 1-fold for 
leucocytes. The authors performed a bacterial plate assay followed by colony counting, 
and assessed log reductions at 3 hours when the test sample was compared to the PBS 
controls. P. aeruginosa, K. pneumoniae, and S. aureus all showed an initial log reduction 
in bacterial numbers 3 hours after spiking into the different preparations, however the 
reductions were lowest with the PG, and bacterial regrowth was seen at 48 hours with all 
preparations. The preparations were most effective against E. coli, where there was a 
large inactivation of bacteria (7.51 to >9.01 log), and no viable colonies for 48 hours after 
spiking. Furthermore, similar antimicrobial activity was seen in different preparations 
regardless of the concentrations of the platelets and leucocytes. As the PG preparation 
appeared to have the lowest antimicrobial effect on these strains, it seems that the use of 
calcium chloride for activation of coagulation could have decreased the bactericidal 
property of the PRP.  Although there were some antimicrobial effects, none of 
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preparations were able to inhibit, B. cereus, B. subtilis, and S. epidermidis. Reassuringly, 
complement-inactivated control preparations did not show any antimicrobial activities. 
Having taken all into account, the authors concluded that plasma complement, rather than 
specifically platelets or leucocytes, are the elements responsible for the antimicrobial 
activity seen against E. coli, K. pneumoniae, and S. aureus.  Chen et al. [22] investigated 
the in vitro antimicrobial activity of APG (autologous platelet-rich gel)  extracted from 
the blood of patients with diabetic dermal ulcers,  against the most common bacteria 
found in diabetic chronic wounds: S. aureus, E. coli and  P. aeruginosa. To mitigate any 
confounding effects of previous IV antibiotics that the patients may have received as part 
of routine care, the blood for the PRP preparation was drawn from patients 8-12 hours 
after antibiotic administration.  PRP was obtained through a double step centrifugation 
procedure and activated with thrombin and calcium gluconate. Comparator preparations 
were: APG, PRP (inactivated), PPP, and APG-APO (autologous platelet gel with 
apocyanin). Apocyanin is an inhibitor of NADPH oxidase activity, and is thus a way to 
study L-PRP antimicrobial activity, whilst excluding the possible antimicrobial 
contribution of leucocytes producing superoxide. PBS was used as a control. Both PLG 
and APG-APO were effective in reducing the bacterial counts of S. aureus compared to 
the PBS control in the first four hours, and were more effective during 24 hours 
compared to PRP and PPP. Since the APG, APG-APO and PRP preparations showed 
antibacterial effects against E. coli and P. aeruginosa compared to PBS (but there was no 
effect with PPP), the authors attribute the antimicrobial effects seen to the prior IV 
antibiotics administered to the patients, rather than the biomaterial preparations. The 
authors concluded that the antimicrobial activity seen against S. aureus is likely not due 
to the inclusion of leucocytes in the PRP preparation, as APG and APG-APO showed a 
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similar antibacterial effect. It is thought that the activity may be attributable to the 
thrombin and calcium gluconate used to activate the platelets. 
 In order to test the antimicrobial activity against Gram negative bacteria that are 
commonly present in enterocutaneous fistula tracts (including E. coli, P. aeruginosa and 
K. pneumoniae), Wu et al. [23] compared three different biomaterials,  and a commercial 
fibrin glue called Bioseal
®
. Blood drawn from 14 healthy volunteers was centrifuged and 
processed to obtain: PLF (platelet-leucocyte fibrin) which is a preparation containing a 
high concentration of platelets (10-fold enrichment from whole blood) and low 
leucocytes (3.9 fold decrease from the baseline) activated with thrombin; PRP (similar 
concentrations of platelets to whole blood and 3.9 fold decrease in leucocytes from the 
baseline) and PPP (poor platelet concentration and no leucocytes). The Kirby-Bauer disc 
diffusion test and bacterial killing assays were used to compare the antibacterial activity 
of the different preparations. Also the levels of complement and antibodies (IgA, IgG, 
IgM, C3, C4) were measured in PLF, PRP and PPP and no significant difference was 
found between the different preparations.  For the microbiological assays a greater 
antibacterial effect was found in with PRP and PLF compared to PPP. However, it was 
noted over time that PLF seemed to lose its antimicrobial effect more than PRP (although 
this was not statistically significant). The commercial fibrin glue (Bioseal
®
) did not show 
any antimicrobial effect. For the bacterial killing assay, the effect seemed only 
bacteriostatic, with the maximum killing of bacteria observed in the first four hours, 
followed by regrowth up to peak numbers at 24 hours. The antimicrobial activity against 
P. aeruginosa was dose-dependent, requiring higher concentrations of the PLF 
preparation than those that were effective for the other two bacterial species. In the in 
vitro study conducted by Intravia et al. [24], different PRP preparations with low and 
high concentrations of platelets and leucocytes were tested to verify the antimicrobial 
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properties against bacteria commonly found in arthroplastic surgery (MSSA, MRSA, S. 
epidermidis (MSSA) and P. acnes). Two different preparations were obtained using 
different centrifugation conditions (Table 2). The preparations contained low (PRPLP), or 
high (PRPHP) concentrations of platelets and leucocytes, and both showed a significant 
decrease in bacterial growth at 8 hours for all of the bacterial samples when compared to 
the controls. PRP rich in leucocytes and platelets (PRPHP) gave a superior decrease of S. 
epidermidis and P. acnes at 8 hours compared to the preparation with negligible inclusion 
of leucocytes and lower platelets (PHPLP). Also, at 1 and 4 hours after MRSA 
incubation, the preparation enriched with leucocytes (PRPHP) showed a stronger growth 
inhibition than the leucodepleted biomaterial (PRPLP).  After 24 hours, significant 
inhibition was still seen for MSSE, MRSA, and P. acnes with both preparations. 
Similarly Lopez et al. [25], compared different preparations of PRP (with low and high 
levels of leucocytes, activated or in their pure form), in terms of their antimicrobial 
properties against MSSA and MRSA. Blood was drawn from 18 healthy horses, and 
using double centrifugation, the authors obtained a range of preparations containing 
different concentrations of platelets and leucocytes. These were enriched respectively by 
1.64 and 2-fold from the blood baseline in the PRP preparation whereas in the LPP 
(leucocyte poor plasma) preparation, the leucocytes count was negligible. The pure form 
of these two products was also compared to the activated form (activated via calcium 
gluconate), and to plasma and to heat-inactivated plasma (IP). With the exception of IP, 
at six hours all blood components significantly inhibited bacterial growth. Furthermore, 
the non-activated form of PRP showed a better bacteriostatic activity against MRSA 
when compared to the activated form (LPG: leucocytes-poor plasma gel) and plasma. 
MSSA showed higher sensitivity to the treatments than MRSA, and PRP against MSSA 
showed the highest bactericidal effect followed by plasma, then LPP, LPG, and PRG. 
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Against MRSA, at 6 hours PRP was again the preparation showing stronger antimicrobial 
effect, whilst at 24 hours LPG and plasma had stronger bacteriostatic effect against 
MRSA. The release of growth factors (PF-4, TGF-β1, PDGF-BB) by the different 
preparations at different incubation times were also measured, but no correlation between 
bacterial counts and leucocytes, platelets, PF-4, TGB-β1, PDGF-BB was recorded 
suggesting that bacteria were not able to denature the growth factors,  and that plasma 
components could be responsible for the  antimicrobial effects observed.  A recent 
publication by Mariani et al. [16] specifically investigated the possible contribution of 
leucocytes in a PRP preparation against different bacteria of relevance to bone, soft tissue 
and wound infections (including MSSA, E. coli, P. aeruginosa, K. pneumoniae, and E. 
faecalis). Two different PRP preparations (including or excluding leucocytes) were 
obtained from 150ml of whole blood, drawn from 10 healthy donors. The preparation 
involved different centrifugation steps as shown in table 2, and resulted in L-PRP 
(leucocyte and platelet rich plasma), and P-PRP (pure platelet rich plasma).   Moreover, 
to investigate whether or not the cryopreserved blood product influenced the 
antimicrobial effect, a third preparation (L-PRP cryo) was obtained by freezing the L-
PRP preparation at −30°C for 2 hours.  All the products were then used in their activated 
form for the experiment. As the three different preparations showed similar antimicrobial 
results (with bacterial growth inhibition observed for to the first 4 hours for all the 
preparations), the authors concluded that the inclusion of leucocytes does not contribute 
significantly to the antimicrobial activity of PRP. The inhibition varied between 1-4 log, 
according to the bacterial strain and experimental conditions tested.  After treatment with 
the three plasma fractions, a time-dependent inhibition of bacterial growth (for up to 4 
hours) and at low bacterial count for E. coli, and P. aeruginosa, and at higher numbers 
for S. aureus, and Enterococcus faecalis was detected. In contrast, there was not a time-
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dependent inhibition of growth with K. pneumoniae.  Generally the quantities and 
abundance of the microbicidal proteins correlated well with growth inhibition, where 
higher quantities of proteins correspond with greater inhibition. Thomsen et al. [14] have 
analysed the phagocytic fitness and bactericidal activity of leucocytes included (at a 
concentration of 55x10
6
/patch) in a multilayer matrix of fibrin and platelets, called a 
leucopatch. The authors observed that the neutrophils included in this preparation are 
active and capable of chemotaxis, phagocytic activity and respiratory burst. When P. 
aeruginosa was mixed with the leucopatch, the production of ROS (measured by 
chemiluminesce) of leucopatch PMNs, was substantial, and the response was 
concentration-dependent.  The production of ROS during phagocytosis of P. aeruginosa 
was also tested in isolated PMNS at a concentration of10
7
cells/ml). The resulting 
chemiluminescence signal was twice as high compared to the signal from leucopatch 
PMNs. When ROS production was tested for a longer time period of 7 days, ROS 
production was still observed at day 4. The chemotactic leucocyte migration was also 
investigated using transwell chambers. The authors found that the leucopatch PMNs were 
capable of migration towards P. aeruginosa. Moreover, bactericidal assay tested 
Pseudomonas aeruginosa in both planktonic and in an alginate-embedded model, 
simulating the biofilm mode of bacteria growth. Serum-opsonized P. aeruginosa was 
exposed to leucopatch, diluted samples were plated and after 24 hours CFU (Colony-
forming unit) were counted. Compared to control (Buffer with P. aeruginosa), strong 
reduction of colonies was observed after 20 minutes of leucopatch exposure and reduced 
further reduced after 90 minutes. Two concentration of bacteria were tested (5 x 10
7
 
CFU/ml and 5 x 10
8 
CFU/ml). The loss of bacteria availability was more evident (99% 
loss of bacteria with respect to the initial inoculum) when the lower concentration of 
bacteria was exposed to the leucopatch. When bacterial growth was tested in alginate 
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beads and disc, mimicking a biofilm model, also antimicrobial activity of the patch were 
detected. The alginate beads and discs with Pseudomonas were exposed to leucopatch for 
2 hours, transferred to tubes containing PBS (phosphate-buffered saline), homogenized, 
serially diluted, plated, and the next day the CFU were counted. After 2 hours, colonies 
count was reduced by 70% when simulating biofilm in form of disc when exposed to 
leucopatch and leucopatch inhibited bacterial growth completely compared to non-
leucopatch control in the alginate beads model.   
In vivo and in vitro studies were conducted by Li et al. [26] to test the antibacterial effect 
of PRP gel and the ideal concentration of bovine thrombin for activation of the PRP. For 
the in vitro study, a killing curve assay was used to test the effect of PRP and PPP gels 
against MSSA, MRSA, Group A Streptococcus, N. gonorrhoeae, Pseudomonas spp. and 
E. coli. PRP gel was obtained from rabbit blood through a two stage centrifugation 
process, and activated using a range of different concentrations of thrombin in calcium 
chloride. Results were compared to PBS controls and to PPP-gel. The concentration of 
platelets and leucocytes in the PRP gel preparation was extremely high (approximately 
10-fold and 4-fold increase from the baseline respectively), and this preparation was 
shown to inhibit MSSA, MRSA, Group A streptococcus and N. gonorrhoeae growth in 
the first 4 hours, after which an increase of bacterial growth was identified. Only high 
concentrations of thrombin produced sufficient antimicrobial activity of the PRP gel 
against N. gonorrhoeae. There was no antimicrobial activity of the PRP gel against 
Pseudomonas spp. and E.coli, and the PPP gel was ineffective for all species.  
DISCUSSION 
In recent years, one of the hottest areas in regenerative medicine has been research 
focusing on enhancing and promoting tissue repair and regeneration [29]. Burns and 
chronic wounds represent a continuing challenge for physicians in terms of treatment, 
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time, and for healthcare services in terms of elevated costs [30,31]. Wound infection is 
one of the major contributors to delays in wound healing and tissue regeneration [32,33]. 
Moreover, as multidrug resistance to antibiotics is becoming a serious threat [34,35], 
research in this field has focused on finding new agents and strategies to fight infection 
[36] and additionally to reduce healing times. New approaches to promote rapid wound 
healing and prevent infection at wound sites are now urgently needed.  
 
 
 
L-PRP versus PRP  
Only four studies have specifically compared the antibacterial properties of autologous 
PRP in the presence and absence of leucocytes or L-PRP [16,20,24,25]. The overall 
conclusion of the authors was that no significant difference between the two preparations 
was found. Most of the authors suggest that the temporal bacteriostatic properties of L-
PRP seem to be caused by either plasma and/or platelet components rather than the 
leucocytes themselves [21,22,25]. However, looking for results on specific bacterial 
strains, Anitua et al. [20], showed that the fraction containing a very high concentration 
of leucocytes (almost 4 times the baseline) was the only preparation able to effectively 
reduce MSSE.  Furthermore Intravia et al. [24], reported that the L-PRP preparations 
(with a high concentration of leucocytes) were superior to PRP (with no leucocytes) 
against MRSA, MSSE and P.acnes. Also compared to whole blood, both preparations 
limited bacterial growth, but for MSSA L-PRP showed a longer inhibition of MSSA (of 
24 hours duration). Moreover, Lopez et al. [25] showed that the non-activated 
preparation enriched with leucocytes gave a better bacteriostatic effect against MSSA (at 
6 and 24 hours) compared to preparations poor in leucocytes. In contrast, the activated 
form of the preparation with poor leucocytes and plasma seemed to perform better than 
the other preparations tested at 24 hours against MRSA. In contrast Mariani et al. [16], 
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concluded that ‘leucocyte presence does not increase microbicidal activity of Platelet-rich 
Plasma in vitro’ in a study where the quantity of leucocytes included in the L-PRP 
preparation was low..  Whole blood was used as a positive control by Intravia et al. [24], 
and in their study the authors showed the poor antimicrobial activity of the whole blood 
compared to the biomaterial enriched with platelets and leucocytes. Moreover, significant 
antimicrobial effect of PRP was seen when leucocytes were at least 2-fold enriched from 
baseline [26]. To evaluate the potential antimicrobial contribution of leucocytes, Chen et 
al. [22] used apocynin in a L-PRP preparation to exclude the possible contribution of 
leucocytes producing superoxide. The authors showed similar antimicrobial activity 
regardless of apocynin, concluding that the antibacterial effect of the biomaterial was not 
due to the inclusion of leucocytes. 
Activation of PRP preparations  
Results are controversial regarding possible relationships between antimicrobial activity 
and the activation of the PRP preparations. Burnouf et al. [21], suggested that the 
activation of platelets by calcium chloride decreased antimicrobial properties against 
selected bacterial strains. Similarly Wu et al. [23] showed thrombin-activated PRP 
preparations have less antimicrobial activity against E.coli, P. aeruginosa and K. 
pneumoniae compared to the inactivated preparations. These findings are thought to be 
due to consumption of complement during the coagulation activation. Also Lopez et al. 
[25] indicated that after 24 hours of incubation, calcium gluconate-activated PRP 
preparations exhibited less antimicrobial activity against MSSA compared to inactivated 
preparations.  When the preparations where tested against MRSA at 6 hours, the strongest 
antimicrobial effect against MRSA was exerted by the non-activated form of the 
leucocyte enriched preparation, whilst at 24 hours the activated form of leucocytes poor 
plasma showed stronger antimicrobial effect compared to the other preparations tested. 
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Controversially, other studies indicate that strongest antibacterial activity is reached when 
PRP is activated with thrombin [22], with the highest concentration of thrombin exerting 
the strongest antimicrobial effect, and with autologous thrombin performing better than 
bovine thrombin [26].  
L-PRP/PRP preparation methods and microbiology assays 
 Due to the heterogeneity of the preparations and the multiple variables in the study 
settings, it is difficult to compare results of studies and reach definitive conclusions 
regarding the relevance of the leucocytes in antimicrobial activity of L-PRP preparations.  
The proportion of the different components included in the biomaterials that exerted the 
strongest antimicrobial properties clearly still remain to be identified.  It is important to 
remember that the in vitro studies may not reflect the clinical scenario, since this 
environment may not mimic the dynamic condition of an in vivo setting where the 
antimicrobial properties of each individual components of the biomaterial may be 
increased, prolonged or even reduced by the complex interaction of cellular signals, and 
dynamic fluid exchange. An example of different results of platelet gel effects against 
bacteria obtained in vitro and in an ex vivo skin model is clearly shown in a recent 
published study. Edelblute et al. [37] demonstrated different antimicrobial performance 
against three strains of bacteria in different settings. No inhibition was seen for 
Pseudomonas spp. in the in vitro experiment, while inactivation of the same strain was 
detected in the ex vivo model. Moreover as suggested by Burnouf et al.[21], ATCC 
(American Type Culture Collection) bacterial strains used in most of the studies, may not 
reflect the bacterial behaviour of clinical isolates. Also different strains showed different 
responses to diverse blood products. This might due to the antimicrobial activity of 
AMPs  directly related to the intrinsic AMP susceptibility phenotype of the infecting Comment [FH1]: Does this need to be 
written in full? 
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bacterial strain, reflecting the point that different bacterial strains have dissimilar 
susceptibility to inhibition by platelet AMPs [38].  
Possible use of L-PRP 
Even with minor variation in timing for different strains and for different preparations, 
the studies included in our review seem to agree that 4 hours is the optimal time of 
incubation, when the maximum decrease in bacterial numbers is achieved. All studies 
agree that the preparations are bacteriostatic, resulting in regrowth, but recognise that L-
PRP preparations are a helpful addition more likely to be used in a clinical setting for 
prophylaxis rather than therapeutically for the treatment of established infection. Authors 
[14,23] suggest to use formulations containing leucocytes and platelets in combination 
after surgical debridement to reduce both the bacterial load (killing bacteria and 
inhibiting biofilm formation [14]), and stimulate healing.   
Are the included leucocytes viable and active?  
The methodology described in the studies to centrifuge and prepare blood products 
should not theoretically damage leucocytes. It is likely that in Burnouf et al. [21], 
leucocytes included in the PRP preparation were no longer viable as the preparations 
were kept frozen until use, therefore the contribution to the antimicrobial effect showed 
by the PRP preparation is likely not due to leucocyte inclusion. 
In the study conducted by Moojen et al. [19] the authors found that neutrophils and 
monocytes were viable and active as showed by the rise of MPO concentration detected 
shortly after the addition of L-PRP to the bacterial culture. Thomsen et al. [14] 
investigated the  phagocytic fitness of leucocytes included in a multilayer matrix of fibrin 
and platelets. The authors observed that the neutrophils included in this preparation were 
active and capable of chemotaxis, phagocytic activity and respiratory burst. Interestingly, 
the authors contradict the general assumption that neutrophils have a short lifespan of less 
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than 24 hours.  Neutrophils in fact showed reduced but oxidative burst activity even after 
7 days, confirming previous published work revealing a neutrophil lifespan of more than 
5 days [39].  
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L-PRP in wound healing: concerns for scarring  
Mindful of all the limitations of the studies included in our review, the overall conclusion 
seems to be that the contribution of leucocytes in a PRP preparation is still poorly 
understood or at least not fully appreciated in the studies so far conducted. On the other 
hand, it is possible to state that none of the papers included in our review strongly suggest 
a remarkable antimicrobial effect specifically due to the leucocytes included in PRP 
preparations. Leucocyte inclusion in the biomaterial should be carefully further evaluated 
especially when the biomaterial is used for wound repair and when scar formation is a 
major concern.  Among all the factors that affect scar quality [33,40], the one that seems 
to have the greatest impact is the time that it takes a wound to heal [40-42]. A large body 
of literature supports the assertion that achieving wound healing within 21 days will 
minimize the scarring. Therefore, a major focus in burns and wound healing research is to 
clarify the pathophysiology of the healing process of a wound, the risk factors related to 
the scarring process, and the conversion of this knowledge into therapeutic solutions. The 
use of PRP in wound healing as an accelerator of wound repair seem to justify its use. 
Several studies are now evaluating the role of leucocytes in wound 
repair[11,43].Cytokines, such as TGF-β1 and TGF β2,  released by leucocytes, have been 
shown to be involved in in cutaneous scarring [44-46]. Their inclusion for wound healing 
and scar formation should therefore be carefully considered.  In particular, further 
investigations should be performed into the antimicrobial and immune-metabolic effects 
of all the subpopulations of leucocytes included in the preparations, in order to create the 
optimal combination.  
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CONCLUSION   
Although the presence or absence of leucocytes in PRP preparations was previously 
neglected, in the last decade more attention has been paid to their role and several studies 
have been conducted to explore both their immuno-metabolic effects and their 
antimicrobial properties.  
In this review, despite a number of studies showing that preparations including 
leukocytes have antimicrobial properties, there is not enough evidence to attribute this 
bactericidal effect to the presence of leucocytes in the biomaterial. PRP preparations, 
with or without leucocytes demonstrated bacteriostatic properties against the majority of 
the bacterial strains tested. Diverse strains of bacteria respond differently to PRP and L-
PRP, some of them requiring the presence of leucocytes (MSSE), and some being dose 
dependent (Pseudomonas spp.). The authors hope that this review will be a groundwork 
for future studies to further explore the contribution of leucocytes in PRP preparation in 
order to obtain an optimal preparation to both fight infection and effectively promote 
wound healing.  
 
LIST OF ABBREVIATIONS  
ESBL: Extended Spectrum Beta Lactamase, IGF-1: insulin-like growth factor 1, MRSA: 
methicillin resistant Staphylococcus aureus, MRSE: methicillin-resistant Staphylococcus 
epidermidis, MSSA: methicillin sensitive Staphylococcus aureus, MSSE: methicillin-
sensitive Staphylococcus epidermidis PBS: phosphate buffered saline, PDGF-BB: 
platelet-derived growth factor BB, PPP: platelet-poor plasma, TGF-β1: transforming 
growth factor beta 1, VEGF: vascular endothelial growth factor. 
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